Xeris Biopharma Holdings
XERS
86 hedge funds and large institutions have $150M invested in Xeris Biopharma Holdings in 2020 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 27 increasing their positions, 21 reducing their positions, and 24 closing their positions.
2,840% more call options, than puts
Call options by funds: $13.4M | Put options by funds: $457K
76% more capital invested
Capital invested by funds: $85M → $150M (+$64.5M)
29% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 21
0% more funds holding
Funds holding: 86 → 86 (0)
0% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 24
30.74% less ownership
Funds ownership: 85.34% → 54.59% (-31%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.91M |
| 2 |
DAM
Deltec Asset Management
New York
|
+$2.38M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
+$1.68M |
| 4 |
D.E. Shaw & Co
New York
|
+$1.34M |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
+$1.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$10.6M |
| 2 |
DM
Deerfield Management
New York
|
-$8.46M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.89M |
| 4 |
Millennium Management
New York
|
-$1.84M |
| 5 |
AGM
Alpine Global Management
New York
|
-$1.79M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PC
101
PA Capital
Richmond,
Virginia
| – | -$73K | -27,420 | Closed |
|
|
HRCM
102
Hawk Ridge Capital Management
Los Angeles,
California
| – | -$64K | -24,000 | Closed |
|
103
SG Americas Securities
New York
| – | -$54K | -20,438 | Closed |
|
|
BFM
104
Boothbay Fund Management
New York
| – | -$51K | -19,190 | Closed |
|
|
CH
105
CVI Holdings
Wilmington,
Delaware
| – | -$39K | -14,626 | Closed |
|
106
State of Wisconsin Investment Board
Madison,
Wisconsin
| – | -$38K | -14,300 | Closed |
|
107
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$49.5K | -12,392 | Closed |
|
|
CCM
108
CAAS Capital Management
New York
| – | -$40K | -10,000 | Closed |
|
109
Group One Trading
Chicago,
Illinois
| – | -$8.72K | -2,180 | Closed |
|
XERS Hedge Fund Activity: Q3 2020 in Review
86 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q3 2020, worth a combined $150M — up 76% from $85M a quarter earlier.
Fund positioning in XERS was balanced in Q3 2020: 24 funds opened new positions, 24 closed out, 27 added to existing stakes and 21 trimmed.
The largest buyer was BlackRock, adding an estimated $2.91M. The largest seller was JP Morgan Chase, cutting an estimated $10.6M.
- 86 institutional investors held Xeris Biopharma Holdings (XERS) as of Q3 2020, unchanged from Q2 2020.
- Funds reported $150M of Xeris Biopharma Holdings stock for Q3 2020, up 76% quarter-over-quarter.
- 24 funds opened new Xeris Biopharma Holdings positions in Q3 2020 and 24 closed out, a net change of 0 holders.
- The largest Xeris Biopharma Holdings buyer in Q3 2020 was BlackRock, an estimated $2.91M added.
- The largest Xeris Biopharma Holdings seller in Q3 2020 was JP Morgan Chase, an estimated $10.6M sold.
Based on aggregated 13F filings for Q3 2020.